Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BVAC C

Next Previous
X
Search
Drug Profile

BVAC C

Alternative Names: BVAC-C

Latest Information Update: 21 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellid Company
  • Class Cancer vaccines; Vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants; Natural killer cell stimulants; Natural killer T cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer

Most Recent Events

  • 31 May 2024 Phase-II clinical trials in Cervical cancer (Combination therapy, Second-line therapy or greater) (unspecified route) prior to May 2024 (NCT04800978)
  • 31 May 2024 Efficacy, Immunogenicity and adverse events data from a phase II trial in Cervical cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Sep 2022 BVAC C is still in phase II trial for Cervical cancer in South Korea (IV) (Cellid Company pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top